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Polyomavirus-like-particles (PLPs) are empty, non-repli-
cative, non-infectious particles that represent a potent
antigen-delivery system [1]. Due to the high immuno-
genicity of heterologous PLPs consisting of the major
polyomavirus coat protein VP1 and a foreign CD8 T cell
epitope at its C-terminus it is possible to protect mice
against B16-OVA melanoma [2]. Here we show that in
mice protective anti-tumour immunity can be already
induced by means of subcutaneous vaccination with par-
ticulate antigens, heterologous VP1-pentamers (8–9 nm
in size). These VP1-pentamers carrying an immunodomi-
nant H-2Kb ovalbumin (OVA)257–264 epitope evoked full
protection in C57BL/6 mice against lethal B16-OVA
melanoma challenge upon twice subcutaneous immuni-
sations in a weekly interval. Furthermore, 60 % of mice
vaccinated with VP1-pentamers carrying an immunodom-
inant H-2Kb-restricted self-epitope of tyrosinase-related
protein 2 (TRP2)180–188 survived to lethal B16-OVA chal-
lenge. This experiment additionally underlines the capac-
ity of PLPs to break T cell tolerance against a differentially
expressed self-antigen. More importantly, heterologous
capsoids of VP1- OVA252–270 (~45 nm in size) cured mice
from B16-OVA melanoma cells that had been adminis-
tered 5 days prior to the first therapeutic treatment. As cor-
relate for protection the number of OVA257–264-specific
CD8 T cells were significantly increased within the splen-
ocyte population of treated mice even in the absence of an
adjuvant (QuilA) as measured by H-2Kb-OVA257–264-PE
tetramers. The weekly treatment intervals appeared to be
crucial for vaccine efficacy due to VP1-specific antibody
interference. These results reveal that heterologous PLPs
and even chimerical polyomavirus-specific pentamers
represent highly efficient antigen carriers for inducing cell-
mediated immunity against malignant diseases underlin-
ing their potency in the fight against cancer.
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